ALLO-647

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameALLO-647
Drug Alias NameAnti-CD52 monoclonal antibody - Allogene TherapeuticsALLO-647
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCAMPATH-1 antigen inhibitors
TargetsCAMPATH-1 antigen
Therapy Area/IndicationsMultiple MyelomaCarcinoma, Renal CellLymphoma, Follicular +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAllogene Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAllogene Therapeutics IncOverland Pharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal CellLymphoma, FollicularLymphoma, B-Cell +[5] 
Inactive IndicationsMultiple MyelomaLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeN/A
Related LinksN/A